eXmoor pharma, the end-to-end cell and gene therapy (CGT) manufacturing partner, today announced the close of a $35 million Series A financing round, from new investor Kineticos Ventures and existing investor MVM Partners. The funding will help launch eXmoor’s Cell and Gene Therapy Centre, a 65,000 sq ft GMP manufacturing facility, purpose-built to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors. Source: eXmoor press release 30/5/2023